TCL Archive Officals: “Separations” in Normal Range as Critics Claim Brain Drain in the Clinic January 17, 2014
TCL Archive Guidelines Working Group Agrees On 4750,00 As Base; Steckel Says AACI May Object To “Freeze” On Core November 21, 1980
TCL Archive Interim Funding: Noncompeting Renewals Reduced By 4 Percent, Competing Current Plus 7 Percent January 8, 1982
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 7, 2004